Gene Editing in Non-Small Cell Lung Cancer: Current Application and Future Perspective
  • Hangxing Wang1,#, Jingyun Fang1,#, Yujiao Wang2,#, Shuo Li2, Zirui Wang2, Wei He2, Nan Wang1, Shuang Luo1, Huimei Zou3,*, Fan Zhang4,5,*
1 Clinical Medical College, Guizhou Medical University, Guiyang, 550004, China
2 Second Clinical Medical College of Lanzhou University, Lanzhou, 730000, China
3 School of Nursing, Guizhou Medical University, Guiyang, 550025, China
4 Department of Pathophysiology, Guizhou Medical University, Guiyang, 550025, China
5 Guizhou Provincial Key Laboratory of Pathogenesis and Drug Research on Common Chronic Diseases, Guizhou Medical University, Guiyang, 550025, China
* Corresponding Authors: Huimei Zou. Email: ; Fan Zhang. Email:
Received 10 February 2022; Accepted 06 March 2022; Issue published 31 March 2022
Abstract
Lung cancer is the most common malignant tumor with the highest morbidity and mortality in the world, and non-small cell lung cancer (NSCLC) accounts for the vast majority of cases. At present, its main treatment methods are still traditional surgery, radiotherapy and chemotherapy, with disadvantages such as a high recurrence rate and limited effectiveness. Therefore, a new, better treatment method is urgently needed. Gene editing technology, as a new genetic engineering approach, has shown great potential in gene research, gene therapy and genetic improvement. It has also emerged as a promising treatment for lung cancer. This paper reviews the current research and applications of gene editing technology in NSCLC and other aspects of NSCLC, the therapeutic principle and mechanism of action, and the existing problems and prospects. This review aims to provide a basis for the prevention and treatment of NSCLC in the future and improve the survival rate of lung cancer patients.
Keywords
Non-small cell lung cancer; gene editing; CRISPR/Cas9
Cite This Article
Wang, H., Fang, J., Wang, Y., Li, S., Wang, Z. et al. (2022). Gene Editing in Non-Small Cell Lung Cancer: Current Application and Future Perspective. Oncologie, 24(1), 65–83.
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.